Cerus Corp. (NASDAQ:CERS) traded up 2.3% during mid-day trading on Friday . The stock traded as high as $6.85 and last traded at $6.75, with a volume of 1,637,088 shares changing hands. The stock had previously closed at $6.60.

Several equities research analysts recently issued reports on the company. FBR & Co reissued an “outperform” rating and set a $10.00 price target on shares of Cerus Corp. in a research report on Tuesday, August 2nd. BTIG Research reissued a “buy” rating and issued a $10.00 price target on shares of Cerus Corp. in a research note on Monday, June 20th. Cantor Fitzgerald reissued a “buy” rating and issued a $9.00 price target on shares of Cerus Corp. in a research note on Thursday, July 7th. Robert W. Baird set a $10.00 price target on Cerus Corp. and gave the stock a “buy” rating in a research note on Saturday, August 6th. Finally, Zacks Investment Research cut Cerus Corp. from a “hold” rating to a “sell” rating in a research note on Tuesday, August 9th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. Cerus Corp. currently has a consensus rating of “Buy” and an average target price of $9.10.

The stock’s market capitalization is $693.29 million. The firm’s 50-day moving average is $6.75 and its 200 day moving average is $6.06.

Cerus Corp. (NASDAQ:CERS) last announced its quarterly earnings data on Thursday, August 4th. The company reported ($0.18) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by $0.01. The firm earned $9.25 million during the quarter, compared to the consensus estimate of $8.88 million. During the same quarter in the previous year, the firm earned ($0.17) earnings per share. The company’s quarterly revenue was up 4.8% compared to the same quarter last year. Equities analysts forecast that Cerus Corp. will post ($0.68) EPS for the current fiscal year.

In related news, CFO Kevin Dennis Green sold 17,150 shares of the firm’s stock in a transaction that occurred on Monday, August 22nd. The stock was sold at an average price of $6.80, for a total transaction of $116,620.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.